These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 34269700

  • 21. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data.
    Khunti K, Kosiborod M, Kim DJ, Kohsaka S, Lam CSP, Goh SY, Chiang CE, Shaw JE, Cavender MA, Tangri N, Franch-Nadal J, Holl RW, Jørgensen ME, Norhammar A, Eriksson JG, Zaccardi F, Karasik A, Magliano DJ, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, CVD-REAL Investigators and Study Group.
    Cardiovasc Diabetol; 2021 Jul 31; 20(1):159. PubMed ID: 34332558
    [Abstract] [Full Text] [Related]

  • 22. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD.
    Circulation; 2019 May 28; 139(22):2528-2536. PubMed ID: 30882238
    [Abstract] [Full Text] [Related]

  • 23. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Berg DD, Wiviott SD, Scirica BM, Gurmu Y, Mosenzon O, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Johanson P, Johansson PA, Langkilde AM, Raz I, Braunwald E, Sabatine MS.
    Circulation; 2019 Nov 05; 140(19):1569-1577. PubMed ID: 31474116
    [Abstract] [Full Text] [Related]

  • 24. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials.
    Kumar K, Kheiri B, Simpson TF, Osman M, Rahmouni H.
    Am J Med; 2020 Nov 05; 133(11):e625-e630. PubMed ID: 32389659
    [Abstract] [Full Text] [Related]

  • 25. Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated meta-analysis.
    Cao Y, Li P, Li Y, Han Y.
    ESC Heart Fail; 2022 Jun 05; 9(3):1942-1953. PubMed ID: 35338608
    [Abstract] [Full Text] [Related]

  • 26. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs.
    Giugliano D, Longo M, Scappaticcio L, Bellastella G, Maiorino MI, Esposito K.
    Cardiovasc Diabetol; 2021 Dec 16; 20(1):236. PubMed ID: 34915880
    [Abstract] [Full Text] [Related]

  • 27. Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Pandey AK, Okaj I, Kaur H, Belley-Cote EP, Wang J, Oraii A, Benz AP, Johnson LSB, Young J, Wong JA, Verma S, Conen D, Gerstein H, Healey JS, McIntyre WF.
    J Am Heart Assoc; 2021 Sep 07; 10(17):e022222. PubMed ID: 34459238
    [Abstract] [Full Text] [Related]

  • 28. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V, Connelly K, Lin P, McFarlane P.
    Curr Med Res Opin; 2019 Jul 07; 35(7):1283-1295. PubMed ID: 30767677
    [Abstract] [Full Text] [Related]

  • 29. Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a systematic review and meta-analysis of randomized trials.
    Ahmad Y, Madhavan MV, Stone GW, Francis DP, Makkar R, Bhatt DL, Howard JP.
    Eur Heart J Qual Care Clin Outcomes; 2022 Jun 06; 8(4):383-390. PubMed ID: 34617565
    [Abstract] [Full Text] [Related]

  • 30. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
    Hinton W, Feher MD, Munro N, Joy M, de Lusignan S.
    Cardiovasc Diabetol; 2021 Jun 28; 20(1):130. PubMed ID: 34183018
    [Abstract] [Full Text] [Related]

  • 31. Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis.
    Wei W, Liu J, Chen S, Xu X, Guo D, He Y, Huang Z, Wang B, Huang H, Li Q, Chen J, Chen H, Tan N, Liu Y.
    Front Endocrinol (Lausanne); 2022 Jun 28; 13():850836. PubMed ID: 35330914
    [Abstract] [Full Text] [Related]

  • 32. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
    Tsai WC, Hsu SP, Chiu YL, Yang JY, Pai MF, Ko MJ, Tu YK, Hung KY, Chien KL, Peng YS, Wu HY.
    BMJ Open; 2022 Oct 14; 12(10):e060655. PubMed ID: 36241355
    [Abstract] [Full Text] [Related]

  • 33. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo-Jack S, Frederich R, Charbonnel B, Mancuso J, Shih WJ, Terra SG, Cater NB, Gantz I, McGuire DK, VERTIS CV Investigators.
    Circulation; 2020 Dec 08; 142(23):2205-2215. PubMed ID: 33026243
    [Abstract] [Full Text] [Related]

  • 34. Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
    Lu J, Tang L, Meng H, Zhao J, Liang Y.
    Diabetes Metab Res Rev; 2019 Oct 08; 35(7):e3169. PubMed ID: 30974510
    [Abstract] [Full Text] [Related]

  • 35. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
    Lin DS, Yu AL, Lo HY, Lien CW, Lee JK, Chiang FT, Tu YK.
    Eur J Endocrinol; 2023 Jul 20; 189(1):S17-S25. PubMed ID: 37474112
    [Abstract] [Full Text] [Related]

  • 36. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis.
    Bhattarai M, Salih M, Regmi M, Al-Akchar M, Deshpande R, Niaz Z, Kulkarni A, Siddique M, Hegde S.
    JAMA Netw Open; 2022 Jan 04; 5(1):e2142078. PubMed ID: 34985519
    [Abstract] [Full Text] [Related]

  • 37. The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism.
    Pan X, Xu S, Li J, Tong N.
    Front Endocrinol (Lausanne); 2020 Jan 04; 11():599355. PubMed ID: 33335511
    [Abstract] [Full Text] [Related]

  • 38. Effects of the Sodium-Glucose Cotransporter Inhibitors on Cardiovascular Death and All-Cause Mortality: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Clinical Trials.
    Eraikhuemen N, Leung S, Warren SB, Lazaridis D, Smith CH, Kearson ML, Marcellus V.
    Am J Cardiovasc Drugs; 2023 Mar 04; 23(2):113-126. PubMed ID: 36572841
    [Abstract] [Full Text] [Related]

  • 39. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Rydén L, Marx N, Brosius FC, Mustafa RA, Agarwal A, Zou X, Mao Y, Asadollahifar A, Chowdhury SR, Zhai C, Gupta S, Gao Y, Lima JP, Numata K, Qiao Z, Fan Q, Yang Q, Jin Y, Ge L, Yang Q, Zhu H, Yang F, Chen Z, Lu X, He S, Chen X, Lyu X, An X, Chen Y, Hao Q, Standl E, Siemieniuk R, Agoritsas T, Tian H, Li S.
    BMJ; 2023 Apr 06; 381():e074068. PubMed ID: 37024129
    [Abstract] [Full Text] [Related]

  • 40. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
    Wang Y, Gao T, Meng C, Li S, Bi L, Geng Y, Zhang P.
    Eur J Med Res; 2022 Dec 29; 27(1):314. PubMed ID: 36581880
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.